AtriCure (NASDAQ:ATRC – Get Free Report) and SS Innovations International (NASDAQ:SSII – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Earnings & Valuation
This table compares AtriCure and SS Innovations International”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AtriCure | $534.53 million | 5.33 | -$11.45 million | $0.30 | 186.60 |
| SS Innovations International | $42.49 million | 6.23 | -$12.13 million | ($0.06) | -22.00 |
AtriCure has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
99.1% of AtriCure shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and target prices for AtriCure and SS Innovations International, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AtriCure | 1 | 4 | 6 | 1 | 2.58 |
| SS Innovations International | 1 | 0 | 0 | 0 | 1.00 |
AtriCure presently has a consensus price target of $62.30, indicating a potential upside of 11.29%. SS Innovations International has a consensus price target of $7.00, indicating a potential upside of 430.30%. Given SS Innovations International’s higher possible upside, analysts plainly believe SS Innovations International is more favorable than AtriCure.
Risk and Volatility
AtriCure has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, SS Innovations International has a beta of -1.52, suggesting that its stock price is 252% less volatile than the S&P 500.
Profitability
This table compares AtriCure and SS Innovations International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AtriCure | 2.52% | 4.01% | 3.03% |
| SS Innovations International | -23.73% | -26.77% | -15.01% |
Summary
AtriCure beats SS Innovations International on 12 of the 14 factors compared between the two stocks.
About AtriCure
AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.
About SS Innovations International
SS Innovations International is a medical technology company focused on developing and manufacturing surgical robotic systems. Its flagship product, the SSI Mantra, is a multi-arm platform designed to support surgeons during minimally invasive procedures. The company’s offerings include surgical instruments and related technologies, such as its SSI Mudra instruments, as well as training and support services for hospitals and clinicians. The SSI Mantra system is designed with features including a surgeon console and 3D visualization, and the company has also emphasized remote surgery and telementoring capabilities.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
